P/E ratio for Jazz Pharmaceuticals (JAZZ)
P/E ratio as of April 2024 (TTM): -76.6
According to Jazz Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -76.5993. At the end of 2022 the company had a P/E ratio of -45.0.
P/E ratio history for Jazz Pharmaceuticals from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -45.0 | 90.04% |
| 2021 | -23.7 | -161.84% |
| 2020 | 38.3 | 136.52% |
| 2019 | 16.2 | -2.56% |
| 2018 | 16.6 | 0.33% |
| 2017 | 16.6 | -0.2% |
| 2016 | 16.6 | -36.48% |
| 2015 | 26.1 | -85.16% |
| 2014 | 176 | 416.09% |
| 2013 | 34.1 | 226.08% |
| 2012 | 10.5 | -18.48% |
| 2011 | 12.8 | -43.26% |
| 2010 | 22.6 | -168.9% |
| 2009 | -32.8 | 12284.8% |
| 2008 | -0.2651 | -82.01% |
| 2007 | -1.47 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.2 | -134.21% | 🇨🇭 Switzerland |
 AmerisourceBergen
ABC | 21.7 | -128.34% | 🇺🇸 USA |
 Endo International
ENDPQ | -0.0001 | -100.00% | 🇮🇪 Ireland |
 Teva Pharmaceutical Industries TEVA | -6.75 | -91.19% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.